Thomas Hutson, DO, PharmD, PhD FACP

997 posts

Thomas Hutson, DO, PharmD, PhD FACP banner
Thomas Hutson, DO, PharmD, PhD FACP

Thomas Hutson, DO, PharmD, PhD FACP

@DrTHut

I am a follower of Jesus, husband, father, brother and physician | Pers Views Only |

Knox City, Texas Katılım Ağustos 2011
645 Takip Edilen912 Takipçiler
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
NEJM
NEJM@NEJM·
Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905 trial) nejm.org/doi/full/10.10… Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nejm.org/doi/full/10.10… #Oncology
NEJM tweet media
English
1
41
108
14.7K
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
“You will never live if you are looking for the meaning of life. Fall in love with some activity and do it! Nobody ever figures out what life is all about and it doesn't matter”—Richard Feynman (1918-1988).
English
3
5
36
2.5K
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Truly humbled by the support of colleagues across the American Society of Clinical Oncology (@ASCO) global community. Thank you for the trust and encouragement—I’m deeply grateful and excited to serve. @OncoAlert @urotoday @OncBrothers @montypal @DrChoueiri @DrRanaMcKay
Neeraj Agarwal, MD, FASCO tweet media
Neeraj Agarwal, MD, FASCO@neerajaiims

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!

English
105
53
345
56.9K
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD·
⭐️SO HAPPY to see Neeraj Agarwal, MD appointed to the ASCO Nominating Committee. A thoughtful leader, generous mentor, great friend for many of us, and someone who truly invests in others—@ASCO will benefit greatly from his voice. 👉 connection.asco.org/do/dr-deb-schr… Congratulations! 👏✨ @neerajaiims @huntsmancancer #TrueGentleman @DrChoueiri @montypal @PGrivasMDPhD @shilpaonc @TiansterZhang @AmandaNizamMD @ZakhariaYousef @UroDocAsh @DrYukselUrun @PBarataMD @jamecancerdoc @crisbergerot @drenriquegrande @oncodaily @OncBrothers @urotoday
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 tweet media
English
5
7
43
2.3K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)@TiansterZhang·
Last minute voter for the @ASCO election? Polls still open until Monday 12/8 3pm eastern! Cast your vote now! @KimrynRathmell @neerajaiims @herbloong best of luck! asco.org/about-asco/asc…
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)@TiansterZhang

Join me - Take 5 mins this wknd to cast your vote in the @ASCO election! Counts for #FASCO points! Fantastic choice leaders on the ballot - @KimrynRathmell for Board, @neerajaiims for nominating committee, @herbloong for international seat on Board. asco.org/about-asco/asc…

English
0
3
19
2.2K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Tom Powles
Tom Powles@tompowles1·
ADC development in urothelial cancer has led to a number of new agents (EGFR/HER2 ADCs NECTIN4/TOPO1) being explored. There has been little focus on biomarkers and more on doublets and triplets. This podcast from #UromigosLive summarised the landscape. podcasts.apple.com/gb/podcast/the…
Tom Powles tweet media
English
4
65
177
13.8K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
Tom is changing bladder cancer SOC, one @myESMO and @ASCO meetings (twice/year) ….with concomitant @NEJM publications! No surprise that Pr. @tompowles1 is Top 10 @Nature people !
Toni Choueiri, MD tweet media
Toni Choueiri, MD@DrChoueiri

Influential, state-of-the-art, as always presentation by @tompowles1 : Biomarker constructive positive trial on ctDNA-guided adjuvant win in MIBC. Atezolizumab improved DFS (HR 0.64; 9.9 vs 4.8 mo) and OS (HR 0.59; 32.8 vs 21.1 mo) vs placebo in ctDNA+ pts. #ESMO25 #BladderCancer @myESMO @DanaFarberNews @DanaFarber @OncoAlert @OncLive

English
1
21
116
20.4K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Daniel Heng
Daniel Heng@DrDanielHeng·
The RAMPART is thankfully positive making it the second adjuvant immunotherapy trial in #kidneycancer along with KN564 with Pembrolizumab. Driven by high risk group. Included non clear cell but should look at that subgroup more. Awaiting OS. #ESMO25 @OncoAlert
Shankar Siva@_ShankarSiva

📣 #ESMO2025: n=565 🇬🇧🇪🇸🇦🇺🇫🇷 RAMPART RCT; Durvalumab + tremelimumab 📈boosts DFS in resected RCC #kidneycancer (HR 0.65, 2-yr 84% vs 78%), esp. in leibovich high-risk pts (HR 0.52, 81% vs 67%). G3+ AES 8% monitoring versus 40% with durva+treme. OS data eagerly awaited! #kcsm

English
0
15
33
2.9K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Tom Powles
Tom Powles@tompowles1·
Adjuvant nivo remains positive for DFS HR-0.73 but still not +ve for OS 0.83 in operable UC #ESMO25 . Enrichment occurred the ctDNA +ves (DFS HR=0.3 & OS HR=0.44) as in IMvigor010. The ctDNA negatives were at much lower risk didn’t seem to benefit from IO (HR-DFS 0.99, OS 0.87)
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
3
46
114
9.5K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
Very nice work in @JCO_ASCO from @VivekSubbiah and team showing in real data the impact of @US_FDA Project Optimus in shaping early Clinical Trials Design. Bravo Vivek !
Vivek Subbiah, MD@VivekSubbiah

🚨 Hot off the press in @ASCO journal @JCOOA_ASCO 👉Pleased to share our study 👉 "Impact of FDA Project Optimus Guidance on Design of Early-Phase Clinical Trials" 📊 Analysis of 367 phase I #oncology trials (2021-2024) reveals Project Optimus is transforming cancer drug development: 📈 Bayesian designs surged 48% → 75% 🎯 30% now include dose-optimization plans ⚖️ Moving beyond max tolerated dose approach 👉This shift toward smarter, more patient-centered trial design marks a pivotal moment in early-phase cancer research @OncoAlert @JCO_ASCO @PamelaKunzMD #ClinicalTrials #CancerResearch #ProjectOptimus #PrecisionMedicine #FDAGuidance Open access Link: ascopubs.org/doi/10.1200/OA…

English
1
12
45
9.1K
Thomas Hutson, DO, PharmD, PhD FACP retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Many colleagues asking how to access #CBM588 for their patients with #kidneycancer. Until the @SWOG P3 opens (led by @PBarataMD), the only legitimate way to access the agent is through the ongoing P1 exploring dose escalation of #CBM588 w nivo/ipi, now in expansion phase (study led by @arafflemd at @cityofhope). Would not use off study until we have confirmation of efficacy/safety in larger trials.
Sumanta K. Pal, MD, FASCO tweet media
English
1
9
29
2.2K

Keşfet

@EUplatinum @OncoAlert @tompowles1 @VincentWenxinXu @YaleCancer @BraunMDPhD @Nature @SmilowCancer